Real Life Sciences
ARARA - Clinical Trial Anonymization and Automation for Policy 70.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
| USD | 2021 | 2022 |
|---|---|---|
| Revenues | 0000 | 0000 |
| % growth | - | 64 % |
| EBITDA | 0000 | 0000 |
| Profit | 0000 | 0000 |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Dealroom estimates
Related Content
Real Life Sciences (RLS) specializes in providing advanced anonymization services and real-world data (RWD) insights for the life sciences sector. The company serves a diverse range of clients including global life sciences companies, service providers, and regulatory organizations. RLS operates in the pharmaceutical and healthcare research markets, focusing on enhancing clinical trial disclosures and regulatory compliance. The business model revolves around offering Software as a Service (SaaS) technology and operational anonymization services, which are delivered through multiple engagement models tailored to client needs. Revenue is generated through subscription fees for their SaaS platform and service fees for their anonymization solutions. RLS leverages advanced Artificial Intelligence and Natural Language Processing to aggregate, categorize, and visualize unstructured social media data, providing comprehensive insights into patient experiences and unmet needs. This helps clients design better patient-centered care and stay ahead of regulatory changes.
Keywords: Anonymization, Real-world data, Clinical trials, Regulatory compliance, SaaS, Life sciences, AI, NLP, Patient-centric, Social media epidemiology.